Kingsley Biotech (01548.HK) announced Legendary Biotech's results for the first quarter of 2024, with total revenue of US$93.91 million, up 158.67% year on year; ordinary equity holders of the parent company should have accounted for a loss of US$597.93 million, a year-on-year narrowing of 46.66%; loss per share was US$0.16.
金斯瑞生物科技(01548.HK)：传奇生物一季度总收入为9399.1万美元 同比增长158.67%
Kingsley Biotechnology (01548.HK): Legendary Biotech's total revenue in the first quarter was 93.991 million US dollars, up 158.67% year-on-year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.